Customs and CBP: What Happens at the Border

Imported prescription drugs face federal border review before they can enter the United States. U.S. Customs and Border Protection (CBP) inspects travelers, baggage, mail, and courier parcels; the FDA determines whether an FDA-regulated drug is admissible. This page explains that division of authority and the risks patients should understand. It does not describe a legal entitlement to import medication.

Who Decides What

CBP officers conduct the physical inspection of travelers’ baggage at ports of entry and of parcels at International Mail Facilities and express courier hubs under Title 19 customs authority.[1] When an examination identifies an FDA-regulated article such as a prescription drug, the admissibility determination over the drug itself rests with the FDA under Section 801 of the FFDCA, codified at 21 U.S.C. § 381.[2] CBP retains its own Title 19 inspection authority and, for controlled substances, Title 21 seizure authority; the DEA holds separate jurisdiction over controlled-substance importation.[3] The FDA states the baseline plainly: in most circumstances, it is illegal for individuals to import drugs into the United States for personal use.[4]

The Traveler Path

A traveler arriving at a U.S. port of entry encounters CBP first. CBP may ask about medications and examine baggage. If a prescription drug is found and referred for FDA review, FDA guidance and enforcement policies may be considered when the agency evaluates admissibility; those policies do not create a legal entitlement to import prescription drugs.[4][5] CBP traveler guidance references a 90-day supply as a general benchmark.[6] That benchmark is not a statutory allowance, not a safe harbor, and not a guarantee that medication will be admitted.

The Mail and Courier Path

Most attempted personal-import medication moves by international mail or courier rather than in a traveler’s baggage. That route carries substantial regulatory risk. CBP examines parcels at International Mail Facilities and may set aside parcels appearing to contain FDA-regulated articles; the FDA then reviews what CBP refers.[5] If the FDA refuses admission, it issues a Notice of FDA Action to the addressee, who may, before final action, present testimony to the agency regarding the admissibility of the article.[7] The opportunity to respond does not mean the shipment will be admitted.

Mail shipments are subject to a destruction authority that personally carried items are not. Under Section 801(a) of the FFDCA, the FDA may administratively destroy a refused drug valued at $2,500 or less — or such higher amount as the Secretary of the Treasury may set by regulation — without offering the usual opportunity to export it. This authority was created by the FDA Safety and Innovation Act of 2012 and implemented by the FDA on April 4, 2016.[8][2] A separate, later law — the Safeguarding Therapeutics Act, enacted January 5, 2021 — extended comparable administrative-destruction authority to refused devices; the FDA’s implementing rule for devices was published May 31, 2024 and took effect July 1, 2024.[9][10] The practical consequence is direct: a refused mailed shipment is not necessarily returned to the sender and may be destroyed after notice and an opportunity to present testimony.

Controlled Substances: A Separate and Stricter Path

Controlled substances do not move through the FDA personal-importation framework. They fall under DEA jurisdiction, and CBP coordinates with the DEA on them. Federal regulation at 21 C.F.R. § 1301.26 governs the narrow circumstances in which an individual may carry a controlled substance across the border for personal medical use — requiring declaration to a customs officer, the original dispensing container, and, for a U.S. resident importing a controlled substance obtained abroad without a prescription, a cap of 50 dosage units.[3][11] These rules are narrow, fact-specific, and stricter than the FDA framework for non-controlled prescription drugs. Because controlled substances are outside this site’s scope and carry separate legal risk, see the companion page on controlled substances.

The Federal Oversight Record

The most detailed public account of how border inspection of personal-import drugs operates comes from Government Accountability Office reviews conducted in 2004–2005, which describe the enforcement environment of that period and are now two decades old.[12] Those reviews documented International Mail Facility operations and inter-agency coordination gaps. The federal government has since taken steps including a 2020 FDA–CBP–ICE memorandum of understanding on coordination, but a current, comprehensive public account of day-to-day border operations in 2026 is not available. Patients should not assume that past reports, prior successful shipments, foreign pharmacy licensing, or anecdotal online accounts predict how CBP or FDA will treat a future shipment.

This page is general information about how federal agencies divide authority at the border. It is not legal advice, not medical advice, and not a prediction of any border outcome. Importing prescription drugs into the United States is generally prohibited under federal law, and agency enforcement policies do not create a legal right to import medication. Consult a U.S.-licensed attorney for legal questions about your circumstances and a licensed prescriber or pharmacist for medical decisions.